Stay updated on CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial
Sign up to get notified when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.
Latest updates to the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page
- Check6 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
- Check13 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check35 days agoChange DetectedNew entries have been added, including a completed status for Julie Adams at AbbVie, while several outdated and inactive listings have been removed.SummaryDifference1%
- Check42 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check49 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study and includes a reference to the Contacts and Locations section.SummaryDifference2%
- Check63 days agoChange DetectedSeveral key pages related to genetics and mental health, including schizophrenia and acute graft-versus-host disease, have been removed from the website.SummaryDifference4%
Stay in the know with updates to CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CVL-231 in Schizophrenia: 10 and 30 mg Doses Clinical Trial page.